Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence

References

• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaNew Engl J Med20053531209122316172203
   PubMed Web of Science ®Google Scholar
• McEvoyJPLiebermanJAStroupTSEffectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatmentAm J Psychiatry200616360061016585434
   PubMed Web of Science ®Google Scholar
• StroupTSLiebermanJAMcEvoyJPEffectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychoticAm J Psychiatry200616361162216585435
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHPengXFariesDMontgomeryWHaddadPMTreatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patientsBMC Psychiatry200994619640279
   PubMed Web of Science ®Google Scholar
• LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry20026389290912416599
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationPractice guideline for the treatment of patients with schizophrenia2nd edArlingtonAmerican Psychiatric Association2004
   Google Scholar
• KaneJMLeuchtSCarpenterDDochertyJPfor Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychiatric DisordersThe expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summaryJ Clin Psychiatry200364Suppl 12S5S19
   PubMed Web of Science ®Google Scholar
• LehmanAFKreyenbuhlJBuchananRWThe Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003Schizophr Bull20043019321715279040
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceSchizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care (update)2009
   Google Scholar
• RANZCPRoyal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disordersAust N Z J Psychiatry20053913015660702
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETFrewerPAlonsoJJonesPBfor SOHO Study GroupThe European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatmentActa Psychiatr Scand Suppl200371512755849
   PubMedGoogle Scholar
• SimKSuAUngvariGSDepot antipsychotic use in schizophrenia: an East Asian perspectiveHum Psychopharmacol20041910310914994320
   PubMed Web of Science ®Google Scholar
• KaragianisJNovickDPecenakJWorldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patientsInt J Clin Pract2009631578158819780867
   PubMed Web of Science ®Google Scholar
• StroupTSLiebermanJAMcEvoyJPResults of phase 3 of the CATIE schizophrenia trialSchizophr Res200910711219027269
   PubMed Web of Science ®Google Scholar
• PriceNGlazerWMorgensternHDemographic predictors of the use of injectable versus oral antipsychotic medications in outpatientsAm J Psychiatry1985142149114922866719
   PubMed Web of Science ®Google Scholar
• ShiLAscher-SvanumHZhuBFariesDMontgomeryWMarderSRCharacteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophreniaPsychiatr Serv20075848228817412849
   PubMed Web of Science ®Google Scholar
• ValensteinMCopelandLAOwenRBlowFCVisnicSAdherence assessments and the use of depot antipsychotics in patients with schizophreniaJ Clin Psychiatry20016254555111488366
   PubMed Web of Science ®Google Scholar
• VehofJPostmaMJBruggemanRPredictors for starting depot administration of risperidone in chronic users of antipsychoticsJ Clin Psychopharmacol20082862563019011430
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association (APA)Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)Washington DCAmerican Psychiatric Association1994
   Google Scholar
• GuyWECDEU assessment manual for psychopharmacologyRockville, MDUS Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs1976
   Google Scholar
• AmadorXFStraussDHYaleSAGormanJMAwareness of illness in schizophreniaSchizophr Bull1991171131322047782
   PubMed Web of Science ®Google Scholar
• HoganTPAwadAGEastwoodRA self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validityPsychol Med1983131771836133297
   PubMed Web of Science ®Google Scholar
• The EuroQol GroupEuroQol – a new facility for the measurement of health-related quality of lifeHealth Policy19901619920810109801
   PubMed Web of Science ®Google Scholar
• WareJEJrSherbourneCDThe MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care1992304734831593914
   PubMed Web of Science ®Google Scholar
• DolanPModeling valuations for EuroQol health statesMed Care199735109511089366889
   PubMed Web of Science ®Google Scholar
• CohenJStatistical Power Analysis for the Behavioral Sciences1st edNew YorkAcademic Press1969
   Google Scholar
• HeresSHamannJMendelRIdentifying the profile of optimal candidates for antipsychotic depot therapy A cluster analysisProg Neuropsychopharmacol Biol Psychiatry2008321987199318948163
   PubMed Web of Science ®Google Scholar
• RemingtonGKwonJCollinsALaporteDMannSChristensenBThe use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophreniaSchizophr Res20079022923717208414
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHZhuBFariesDLacroJPDolderCRA prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophreniaJ Clin Psychiatry2006671114112316889456
   PubMed Web of Science ®Google Scholar
• WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv20045588689115292538
   PubMed Web of Science ®Google Scholar
• WestJCMarcusSCWilkJCountisLMRegierDAOlfsonMUse of depot antipsychotic medications for medication nonadherence in schizophreniaSchizophr Bull200834995100118093962
   PubMed Web of Science ®Google Scholar
• OlfsonMMarcusSCAscher-SvanumHTreatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidoneSchizophr Bull2007331379138717470444
   PubMed Web of Science ®Google Scholar
• BitterITreuerTDyachkovaYMartenyiFMcBrideMUngvariGSAntipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) studyEur Neuropsychopharmacol20081817018017884390
   PubMed Web of Science ®Google Scholar
• ChongMYTanCHFujiiSAntipsychotic drug prescription for schizophrenia in East Asia: rationale for changePsychiatry Clin Neurosci200458616714678459
   PubMed Web of Science ®Google Scholar
• YangYKTarnYHWangTYPharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costsPsychiatry Clin Neurosci20055938539416048443
   PubMed Web of Science ®Google Scholar
• ShinfukuNTanCHPharmacotherapy for schizophrenic inpatients in East Asia – changes and challengesInt Rev Psychiatry20082046046819012132
   PubMed Web of Science ®Google Scholar
• SwartzMSWagnerHRSwansonJWThe effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE studySchizophr Res2008100395218191383
   PubMed Web of Science ®Google Scholar
• HeresSSchmitzFSLeuchtSPajonkFGThe attitude of patients towards antipsychotic depot treatmentInt Clin Psychopharmacol20072227528217690596
   PubMed Web of Science ®Google Scholar
• PatelMXde ZoysaNBernadtMDavidASA cross-sectional study of patients’ perspectives on adherence to antipsychotic medication: depot versus oralJ Clin Psychiatry2008691548155619192437
   PubMed Web of Science ®Google Scholar
• TaylorDMYoungCLMaceSPatelMXEarly clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patientsJ Clin Psychiatry2004651076108315323592
   PubMed Web of Science ®Google Scholar
• HeresSHamannJKisslingWLeuchtSAttitudes of psychiatrists toward antipsychotic depot medicationJ Clin Psychiatry2006671948195317194274
   PubMed Web of Science ®Google Scholar
• PatelMXde ZoysaNBakerDDavidASAntipsychotic depot medication and attitudes of community psychiatric nursesJ Psychiatr Ment Health Nurs20051223724415788043
   PubMedGoogle Scholar
• PatelMXNikolaouVDavidASPsychiatrists’ attitudes to maintenance medication for patients with schizophreniaPsychol Med200333838912537039
   PubMed Web of Science ®Google Scholar
• PerkinsDOPredictors of noncompliance in patients with schizophreniaJ Clin Psychiatry2002631121112812523871
   PubMed Web of Science ®Google Scholar
• FentonWSBlylerCRHeinssenRKDeterminants of medication compliance in schizophrenia: empirical and clinical findingsSchizophr Bull1997236376519366000
   PubMed Web of Science ®Google Scholar